way, presumably in the Golgi apparatus, as well as on the cell surface. In contrast, ECE-2 probably functions in highly acidified compartments of the secretory pathway, including a portion of the trans-Golgi apparatus. These isozymes also appear to have different functions during embryonic development (9) . Targeted disruption of the ECE-1 gene in mice revealed that ECE-1 is the major enzyme involved in the activation of big ET-1 and big ET-3 at specific developmental stages. Importantly, it appears that loss of ECE-1 protein cannot be compensated for by ECE-2.
Endothelin receptors
ET A and ET B have been isolated and cloned from human tissues (2) . Both subtypes belong to the seven-transmembrane-domain-spanning, G-protein-coupled receptor superfamily (6) . ET receptors are widely expressed in all tissues, consistent with the physiological role of ET-1, the most abundant isoform, as a ubiquitous endothelium-derived vasoactive peptide contributing to the maintenance of normal vascular tone. ET receptors are also localized to non-vascular structures, such as epithelial cells, and expressed in the central nervous system. ET-1 stimulates proliferation in a number of different cell types, including smooth muscle cells (mainly via the ET A subtype) and astrocytes (via ET B ). In human blood vessels, ET A receptors are present mainly on vascular smooth muscle cells, and are chiefly responsible for contraction whereas ET B receptors mediate vasodilatation. The mechanisms of ET A activation by endothelins and signal transfer mechanism of vascular smooth muscle contraction is schematically shown in Fig 1 [ (21) .
Non-vascular ET B receptors in organs including the kidney may beneficially clear ET-1 from the circulation (6). All these receptors have become important targets for drugs developed to inhibit vasoconstrictor actions (19) .
It is widely accepted that the vascular, cardiac, and renal adverse effects of ET-1 are mediated by ET A , while activation of ET B receptors leads to beneficial effects such as: attenuating the vascular and cardiac hypertrophic effects of ET-1 as well as the vasodilatory action of this peptide (1).
Endothelin receptors agonists
Natural ET agonists are all endogenous ET isoforms and ET receptors to be classified according to their rank order of potency for the individual ETs (5). Other natural ET agonists are sarafotoxins, toxic peptides from the venom of mole viper Atractaspis engaddensis (burrowing asp), which may pose a serious threat to humans. At present, four sarafotoxins (STX) are known: S6a, S6b, S6c, and S6d (3, 30) . A new member of the endothelin/sarafotoxin family of vasoconstrictor peptides, bibrotoxin (BTX), was isolated from the venom of the burrowing asp Atractaspis bibroni (4) . The primary structure of all known endothelins, sarafotoxins and bibrotoxin are summarized in Tab. 1. They are 21-amino acid peptides with high degree of similarity whose structure consists of two rings formed by intra-chain disulphide bonds. 21 ]ET-1(9-21) Peptide antagonists: 
The venom from the snake A. engaddensis has a very high lethal potency, with an i.v. LD 50 of 0.06-0.075 mg.kg -1 body weight in mice. The onset of action of the venom is rapid (30-45 min) and death results from seemingly neurotoxic effects. However, even at high concentrations, the venom does not block contractions of skeletal muscles that are directly or indirectly stimulated. The changes observed in the ECG are similar to those recorded in human victims (18) and are the result of an A-V block that is caused by an apparent direct action of the venom on the heart (34). Concerning ETs already a low dose of ET-1 has a lethal effect in experimental animals by inducing disturbances in the cardiovascular system (16) .
Endothelins and sarafotoxins are not selective agonists of ET A and ET B receptors. Until now, non-selective ET A receptor agonists have been described in the literature. Recently, [D-Lys 9 ]cyclo(11-15) ET-1(9-21) was described as a specific full agonist of ET A receptors, being under two orders less potent than ET-1 (EC 50 :2.3x10 -7 vs 6.8 x 10 -9 M). Interestingly, even a linear formylated analogue, [Ala 11, 15 , Trp(For) 21 ]ET-1(9-21), showed a selective ET A activity (EC 50 :3.0 x 10 -6 M). These peptides are the first compounds showing a significant bioactivity in an ET A pharmacological preparation while being inactive in an ET B paradigm (20) .
As regard ET B receptor, sarafotoxin S6c and the truncated, linear synthetic analogues BQ3020 ([Ala 11, 15 ]acetyl-ET-1- (6-21)) (15) 
Endothelin receptors antagonists
Antagonists are classified as ET A -selective, ET B -selective, or non-selective mixed antagonists that display similar affinities for both receptor subtypes. However, only ET A -selective or ET A /ET B antagonists are currently being evaluated in clinical trials. Nevertheless, ET B -selective antagonists are also known.
The most highly selective peptide antagonists (4-5 orders of selectivity) for the ET A receptors are the cyclic penta- (29) . A peptide structurally similar to FR139317 has been radiolabelled, [ 125 I]PD151242, which displays subnanomolar affinity for the ET A subtype (7). BQ123 is also available as a tritiated analogue, and a non-peptide antagonist, [ 125 I]PD164333, displays high affinity and selectivity for this subtype.
Generally more potent non-peptide antagonists for the ET A receptors, such as PD156707, SB234551, L754142, A127722, and TBC11251 are known and some of them are characterized in Tab. 2. A limited number of peptide (BQ788) and non-peptide (A192621) ET B antagonists have also been developed. Some of them are summarized in Tab. 2. They are generally less potent than ET A antagonists and display lower selectivity (usually only 1 to 2 orders of magnitude) for the ET B receptor. Radioligands highly selective for either ET A ( 125 I-PD151242, 125 I-PD164333, and 3 H-BQ123) or ET B receptors ( 125 I-BQ3020 and 125 I-IRL1620) have further consolidated classification into only these two types, with no strong molecular or pharmacological evidence to support the existence of further receptors in mammals.
Endothelin receptors antagonists in clinical development
While peptide antagonists are useful as research tools, their therapeutic use is limited by the fact that they can only be administered i.v. and have a short duration of action. Being peptides, they are degraded in the gastrointestinal tract by proteolytic enzymes.
The limitations of peptide antagonists have been partly overcome by non-peptide antagonists (5) . ET receptors antagonists in clinical trial are summarized in Tab. 3. Manipulation of the activity of ET-1, especially using ET receptor antagonist, has allowed the further elucidation of the role of this neurohormonal system and development of novel therapeutic strategies in the treatment of heart failure (28) . To date, published clinical studies of these agents have involved relatively small numbers of patients with severe heart failure, followed for a relatively short time period, and have mainly examined surrogate endpoints. Large-scale trials that address to significant clinical outcomes are ongoing and their results forthcoming. A key question that remains is whether selective ET A or dual ET A /ET B receptor blockade will be more effective (1) .
The same refers to utilization of ET antagonists in other pathological conditions, such as pulmonary arterial hypertension (PAH), subarrachnoid hemorrhage or hepatorenal syndrome. Bosentan (Tracleer) (Fig. 2) was the first ET antagonist approved by the Food and Drug Administration for the treatment of pulmonary arterial hypertension (8) and recently tezosentan (Veletri) has been designated for the same indication (17) and is under investigation for acute heart failure. The development of bosentan, a novel, well-tolerated, orally active endothelin antagonist, has significantly changed the therapeutic approach to PAH. Recent clinical trials have demonstrated that treatment with bosentan produces favourable effects on cardiopulmonary haemodynamics (22) . Also tezosentan, dual ET A /ET B receptor antagonist that has demonstrated efficacy in improving cardiac index and reducing pulmonary capillary wedge pressure in patients with acute, decompensated heart failure, was introduced into clinical practice recently (31). 
Conclusions
The ET system plays an important role in the pathophysiology of a variety of cardiovascular diseases including congestive heart failure, essential and pulmonary hypertension, renal failure, and cerebrovascular disease. The biological effects of ET-1 on its target organs are mediated by two receptor types: ET A and ET B . It is widely accepted that the vascular, cardiac, and renal adverse effects of ET-1 are mediated by ET A , while activation of ET B receptors leads to beneficial effects such as: attenuating the vascular and cardiac hypertrophic effects of ET-1 as well as they mediate the vasodilatory action of this peptide (activation of ET B1 -receptor subtype). In the last decade, a plenty of peptide and non-peptide ET-1 antagonists have been developed. Several clinical studies have revealed that ET-1 antagonists are clinically beneficial therapeutic agents for the treatment of several cardiovascular diseases, leading to the approval of bosentan (ET A /ET B antagonist) for the treatment of pulmonary hypertension. 
